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BACKGROUND. Stromal cell-derived factor-1 (SDF-1 or CXCL12) and CXCR4 are key
elements in the metastasis of prostate cancer cells to bone—but the mechanisms as to how it
localizes to the marrow remains unclear.
METHODS. Prostate cancer cell lines were stimulated with SDF-1 and evaluated for
alterations in the expression of adhesion molecules using microarrays, FACs, and Western
blotting to identify avb3 receptors. Cell–cell adhesion and invasion assays were used to verify
that activation of the receptor is responsive to SDF-1.
RESULTS. We demonstrate that SDF-1 transiently regulates the number and affinity of avb3
receptors by prostate cancer cells to enhance their metastatic behavior by increasing
adhesiveness and invasiveness. SDF-1 transiently increased the expression of b3 receptor
subunit and increased its phosphorylation in metastatic but not nonmetastatic cells.
CONCLUSIONS. The transition from a locally invasive phenotype to a metastatic phenotype
may be primed by the elevated expression of avb3 receptors. Activation and increased
expression of avb3 within SDF-1-rich organs may participate in metastatic localization. Prostate
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INTRODUCTION
Bone metastasis is one of the most severe complica-
tions of prostate cancer and is a leading cause of death.
Understanding the molecular mechanisms that regu-
late metastasis will facilitate the identification of novel
therapeutic strategies and targets to reduce metastatic
disease. Recent studies indicated that tumor cell
migration and metastasis are not random processes;
rather, chemokines and chemokine receptors play a
central role in determining the metastatic destination of
tumor cells [1–12]. Malignant cells from different types
of tumors express a variety of chemokine and chemo-
kine receptor expression profiles, but CXCR4 is
expressed by all tumors that metastasize to bone [1].
CXCR4 belongs to a unique class of chemokine receptors
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that appears to have only one ligand, namely stromal
cell-derived factor-1 (SDF-1 or CXCL12). SDF-1 is
produced by the bone marrow stroma and by stromal
cells of mesenchymal origin including osteoblasts and
endothelial cells [13–15]. SDF-1 and CXCR4 play key
roles in the metastasis of hematopoietic cells to bone
marrow [16–18]. Several groups (including ours) have
demonstrated that the SDF-1/CXCR4 axis plays a
crucial role in the metastasis of malignant hematopoietic
and nonhematopoietic cells to marrow [12,13,19,20].
Evidence that supports the aforementioned conclusion
includes the fact that native prostate cancer cells and
prostate cancer cell lines express CXCR4, adhere to
endothelium, and migrate in response to SDF-1 [13,21].
In animal models, blockade of SDF-1 and CXCR4 in
prostate cancer cells prevents both metastasis and tumor
growth [13], but how the SDF-1/CXCR4 axis determines
the invasion patterns of prostate cancer cells is unclear.
Cancer cell adhesion to the vascular endothelium is a
crucial component of the metastatic cascade; the adhesion
process is regulated largely by selectins and integrins
[22,23]. Tissue-selective trafficking of tumor cells to
different organs is thought to be mediated by adherence
of metastatic cells to particular types of endothelial cells.
For example, prostate cancer cells adhere preferentially to
human bone marrow endothelial (HBME) cells versus
other types of vascular endothelial cells [24]. Recent
studies revealed that the heterodimeric transmembrane
integrin avb3 receptor may be involved in adhesion,
migration, invasion, growth, and angiogenesis in many
types of tumors [25,26]. Furthermore, fewer avb3 recep-
tors are expressed in primary lesions and relatively
poorly invasive lines of cancer cells, such as LNCaP cells
[27], than in more aggressive cell types [28,29].
In the present study, we demonstrate that SDF-1
stimulates an increase in the expression of activated avb3
receptors in two lines of metastatic prostate cancer,
namely PC3 and LNCaP C4-2B, but does not affect avb3
receptor expression in nonmetastatic LNCaP cells. This in
turn enhances adhesion and invasion to extracellular
matrix by prostate cancer cells in vitro. We speculate that
during the transformation of a locally invasive phenotype
into a metastatic phenotype, an increase in the expression
of avb3 receptors may be central to the metastatic cascade;
specifically, we hypothesize that once cells enter the
vasculature and reach tissue within which SDF-1 is
expressed abundantly, expression and activation of avb3
receptors by SDF-1 promotes metastasis.
MATERIALSANDMETHODS
Cell Lines
Prostate cancer cell lines (CaP) (PC3, LNCaP C4-2B,
and LNCaP), and the bone marrow endothelial cells
(HBME) were cultured in RPMI medium 1640, supple-
mented with 10% FBS, 1% penicillin-streptomycin, and
1% L-glutamine (Invitrogen Corp., Carlsbad, CA). The
human PC3 cells were originally isolated from a
vertebral metastasis and were obtained from American
Type Culture Collection (Rockville, MD). LNCaP cells
were isolated from a lymph node of a patient with
disseminated bony and lymph node involvement. The
LNCaP sub lines (C4-2B cells) were derived from the
parental LNCaP cell lines that were serially passaged
in mice to obtain a more metastatic cell line [30].
The HBME cells were isolated from a normal
Caucasian male and immortalized with SV40 large
T-antigen [24].
Reagents andAntibodies
Recombinant human SDF-1 and the isotype IgG1
were purchased from R&D Systems (Minneapolis,
MN); the anti-avb3 (LM609), anti-b3 (MAB2008), and
anti-av antibodies were obtained from Chemicon Corp.
(Temecula, CA); the monovalent ligand-mimetic anti-
body WOW-1 Fab was the kind gift of Dr. Sanford
Shattil (Scripps Research Institute, La Jolla, CA); the
anti-b3(1A2) antibody was the gift of Dr. Scott D.
Blystone (SUNY Upstate Medical University, Syracuse,
NY), the PE-conjugated goat anti-mouse IgG1 was
purchased from BD Biosciences (Franklin Lakes, NJ),
the Alexa Fluor1 488F(ab0)2 fragment of goat anti-
mouse IgG (HþL) and VybrantTM CFDA-SE cell tracer
kits (V-12883) were obtained from Molecular Probes
(Eugene, OR). The C3 exoenzyme was purchased
from Calbiochem (San Diego, CA). The ProtOnTM
Fluorescein labeling kit (PLK-1201) was obtained from
by Vector Laboratories (Burlingame, CA). Cytochalasin
D, cyclohexamide, brefeldin A, human thrombin,
purified human vitronectin, pertussis toxin (PTX),
anti-phospho- b3 integrin [pTyr773], anti-a-tubulin
antibody, and the in vitro toxicology assay kits
using 23-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT) were purchased
from Sigma Chemical Corp. (St. Louis, MO).
Adhesion toHBMECells
CaP cell lines were labeled for 30 min with 10 mM
carboxy-fluorescein diacetate, succinimidyl ester
(CFD-SE, Molecular Probes), washed and rested for
an additional 30 min. Labeled cells were stimulated
with 0–200 ng/ml SDF-1 at 378C for 45 min and 1 105
cells were deposited directly onto HBME monolayers,
spun at 500 rpm for 5 min, and binding performed for
15 min at 48C. Total fluorescent counts and specific
binding were quantified on a 96-well fluorescent plate
reader (IDEXX Research Products, Westbrook, ME)
after extensive washing with Caþ2/Mgþ2 PBS.
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IntegrinAdhesionAssay
Cell adhesion kits for avb3 and b1 (Chemicon) were
used to assess the affinity of avb3 and b1 integrins on
CaP cells. For these studies, the cells were detached
from culture with PBS/EDTA, rested for 30 min, and
seeded on to the anti-integrin antibody-coated plates
according to the manufacturer’s instructions. SDF-1
(0–200 ng/ml) or thrombin (1 IU/ml) as a positive
control [31] were used to stimulate the cells for 2 hr at
378C. Adhesion was quantified using a multi-well
scanning spectrophotometer (Molecular Devices Corp.,
Sunnyvale, CA) at 540 nm.
Cell Adhesion toMatrix Proteins
Microtiter plates were coated overnight with vitro-
nectin or osteopontin (1 mg/ml, R&D Systems), washed
twice with PBS, and nonspecific binding blocked with
1% BSA in PBS for 1 hr at 378C. CaP cell lines were
detached using a cell dissociation solution (Sigma), and
washed twice with PBS. The cells were suspended in
RPMI 1640 medium and incubated in the presence or
absence of anti-avb3 (LM609) antibody or an isotype-
matched control (R&D systems) for 15 min on ice to a
final dose of 10 mg/ml. Thereafter the cells were seeded
at 1 105 cells/well in the presence or absence of SDF-1
at 378C for 1–2 hr. After the removal of the nonadherent
cells, the adherent cells were quantified using XTT.
InvasionAssays
BD BioCoatTM matrigelTM invasion chambers
(Chemicon) were used to assess the invasive activities
of CaP cells. After pretreatment of the cells with 15 mg/
ml anti-avb3 antibody or an IgG1 isotype-matched
control for 15 min, the cells were placed in the upper
well (3 105 cells/well) of the invasion chamber. SDF-1
(200 ng/ml) or PBS vehicle were added to the lower
chambers also in RPMI containing 1% FBS. After 24 hr
at 378C, 40 or 80ml of 5 mg/ml MTT (Sigma) were added
to the upper/lower chambers, respectively, for an
additional 4 hr. The nonmigrating cells were removed
with cotton swabs and the purple residues representing
the migrated cells were solubilized in 0.5 ml isopropa-
nol. The plate was rocked for 30 min at a medium speed,
and 100 ml was transferred from each well into a 96-well
plate and read at 595 nm.
Real TimeRT-PCR
Confluent CaP cell lines (LNCaP, LNCaP C4-2B, and
PC3) were treated with 0–200 ng/ml SDF-1 for 2 hr at
378C. The cells were lysed using an RNeasy Mini Kit
(Qiagen, Valencia, CA). RNA integrity and purity was
checked by electrophoresis with ethidium bromide and
absorbance at A260/A280. First strand cDNA synthesis
was generated with 1 mg of total RNA using random
hexamers and SuperScriptTM II RT Kit (Invitrogen).
Amplification primers were designed using PrimerEx-
pressTM software (Applied Biosystems, Foster City,
CA) to cross intron/exon boundaries and were
validated by sequencing the resulting product by the
University of Michigan DNA Sequencing Core Facil-
ities. The sequences of the forward and reverse primers
of av were 50-GAAAAGAATGACACGGTTGC and
50-AGTGATGAGATGGTCCCGCT, respectively. The
sequences of the forward and reverse primers of b3
were 50-ACTGCCTGTGTGACTCCGACT and 50-CGC
GTGGTACAGTTGCAGTAG. Quantitative RT-PCR
was performed by using an ABI PRISM 7700
instrument (Applied Biosystems). PCR was performed
with 12.5 ml of a SYBR1 PCR master mixture (Applied
Biosystems), each of the primers at a concentration of
80 nM, and 1 ml of the RT product in a total volume of
25 ml. The two-step PCR reaction (958C for 15 sec, 608C
for 60 sec) was run for 40 cycles after an initial single
cycle of 958C for 10 min to activate the Taq polymerase.
The mRNA levels were expressed in relative copy
numbers (% control) normalized against GAPDH.
The sequences of the forward and reverse primers of
GADPH were 50-AGCCACATCGCTCAGACACC and
50-CCAATACGACCAAATCCGTTG. Standard curves
were constructed from serial dilutions of GAPDH, av
and b3 cDNAs generated clones derived from PCR
products.
FlowCytometry
In some cases CaP cells were pretreated with
cytochalasin D (10 mM, 1 hr), cyclohexamide (30 mg/ml,
2 hr), and brefeldin A (10 mg/ml, 4 hr) prior to removal
from culture. CaP cells were then incubated with 0–
200 ng/ml SDF-1 in Hanks Buffered Saline Solution
(HBSS, Life Technologies) at 378C for 15–45 min. Total
avb3 was determined by staining the cells with
mAb1960H (LM609) PE (1:200) in HBSS for 30 min on
ice. PE-conjugated goat anti-mouse IgG1 (clone
MOPC21, Sigma) served as negative control. Activated
avb3 levels were identified with the ligand mimetic
antibody Fab WOW-1 (10 mg/ml) [32] in HBSS for
30 min at 228C. Detection of the WOW-1 reagent was
performed with the Alexa Fluor1 488F(ab0)2 fragment
of goat anti-mouse IgG (HþL) antibody at a 1:200
dilution on ice for 30 min. Binding of cell matrix
components to SDF-1-treated (10 min at 258C) cells was
performed using fluoroscein-labeled human vitronec-
tin (ProtOnTM Fluorescein labeling kit (PLK-1201)
(Vector Laboratories)) followed by fixation in 1%
paraformalehyde in PBS. Stained cells were analyzed
on a FACS Calibur flow cytometer (Becton Dickinson,
Mountain View, CA).
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Western Blot and Immunoprecipitation
CaP cells were pretreated with 500 ng/ml pertussis
toxin (PTX, Sigma) for 1.5 hr at 378C and washed with
PBS. After stimulation with SDF-1 (0–200 ng/ml), the
cells were lysed (25 mM HEPES, 300 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 0.5 mM DTT,
20 mM beta-glycerophosphate, 0.1 mM Na3VO4,
and 2% protease inhibitor cocktail (Sigma)). The lysates
were precleared by centrifugation and separated on 8%
SDS–PAGE gels, and transferred to polyvinylidene
difluoride (PVDF) membranes. The membranes
were blocked in 0.1% TBST and 5% nonfat dry
milk, and incubated with anti-phospho-integrin b3
[pTyr773] (Sigma). Total av and b3 integrin subunits
were detected with monoclonal antibodies (SAP)
(Chemicon). Secondary anti-mouse HRP antibody
was used in conjunction with ECL for band detection
(Amersham Biosciences, UK). Normalization of the
membranes was performed using an anti-a-tubulin
antibody.
Cells treated with the exoenzyme C3 (1 107 cells/
10 mg/ml for 1.5 hr at 378C) were stimulated with SDF-1
(200 ng/ml or vehicle) and lysed in 100 ml of the buffer
described above. The lysates were precleared for 1 hr at
48C with gelatin-sepharose and immunoprecipitated
with goat anti-mouse sepharose beads coated with anti-
b3 monoclonal antibody (1A2) for 2 hr at 48C. Samples
were separated on 8% SDS–PAGE gels, and probed
with the anti-phospho-integrin b3 [pTyr
773] (Sigma)
antibody. One-tenth of the total lysates were probed for
total b3 using the anti-b3 monoclonal antibody (SAP)
(Chemicon).
Statistical Analysis
Each experiment was repeated a minimum of three
times. Numerical data are expressed as mean the
standard deviation. Statistical analysis of the results
was performed with STATISTICA 6.0 (StatSoft, Inc.,
Tulsa, OK) using ANOVA followed by post hoc
Newman–Keuls test for comparison between groups,




To determine whether SDF-1a regulates the adhe-
sion of prostate cancer cells to HBME cells, we used
cell–cell adhesion assays. Treatment of two lines of
prostate cancer cell that metastize to bone marrow (PC3
and LNCaP C4-2B cells) with SDF-1a increased the
adhesiveness of these cells (Fig. 1A). By contrast,
the adhesiveness of nonmetastatic LNCaP cells was
not altered even at the highest dose of SDF-1a tested
(Fig. 1A).
To explore which adhesion molecules are involved
in the SDF-1-induced increase in adhesiveness, DNA
microassays were performed to compare LNCaP C4-2B
cells stimulated with SDF-1 (200 ng/ml for 2 hr) to
unstimulated LNCaP C4-2B cells. The b3 integrin
subunit and CD164 were among the adhesion mole-
cules that were most responsive to SDF-1 (data not
presented). Because expression of the b3 integrin
subunit (in affiliation with the av subunit) is elevated
in metastatic prostate tumors [26,33,34], we further
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Fig. 1. Theeffectofstromalcell-derivedfactor-1a (SDF-1a)onthebindingofprostatecancercells tohumanbonemarrowendothelial(HBME)
cells andplates coatedwith an anti-integrinavb3 receptor antibody.A:Fluorescentprostate cancercellswere treatedwithvehicle or SDF-1a
(30 ^ 45min) before being seeded onto HBMEmonolayers for15min at 48C. After washing away the nonadherent cells, adherent cells were
counted.B,C:Prostate cancercellswere treatedwithSDF-1a (0 ^200ng/ml) for2hr at378Cbeforebeingplatedontoplates coatedwithanti-
avb3(A)oranti-b1(C)antibodies.Nonadherentcellswereremovedbeforeadherentcellswerecounted.Asapositivecontrol,thrombin(1IU/ml)
wasusedtoactivateavb3receptors.Data arepresentedas themean SDnumberof fluorescentcountsquantifiedin threeindependentinves-
tigations,eachofwhichwasperformedin triplicate. *P< 0.05, **P< 0.01, and***P< 0.001versus thecorrespondingvehicle-treatedgroup.
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explored the role of avb3 receptors in the response to
SDF-1. The relationship of CD164 to prostate cancer
will be presented in a companion manuscript [52].
Adhesion assays were used to assess the affinity of
avb3 receptors expressed at the cell surface of prostate
cancer cell lines that were exposed to the SDF-1. As a
positive control, thrombin was used to activate avb3
receptors (Fig. 1B) [31]. SDF-1 significantly increased
the binding of PC3 and LNCaP C4-2B cells to anti-avb3
receptor-coated plates. The enhanced binding of
LNCaP cells decreased after 2 hr (Fig. 1B). As a control
for specificity, we also examined the effects of SDF-1 on
b1 integrin. Treatment of prostate cancer cells with SDF-
1ahad no effect on binding to plates coated with anti-b1
integrin antibodies (Fig. 1C).
SDF-1Enhancesavb3 Receptor-Mediated Prostate
CancerCell Adhesion and Invasion
To further explore how SDF-1 regulates adhesion,
the adhesion of SDF-1-stimulated prostate cancer cells
to theavb3 receptor ligands vitronectin and osteopontin
was examined. SDF-1 treatment dramatically increased
the adhesion of metastatic PC3 and LNCaP C4-2B cells
to vitronectin (Fig. 2A,B) and osteopontin (data not
presented). Inclusion of the anti-avb3 receptor anti-
body, LM609, reduced the basal binding of PC3 cells
and inhibited the SDF-1-induced enhancement of
binding (Fig. 2A). Similar results were obtained for
LNCaP C4-2B cells (Fig. 2B), although the anti-avb3
receptor antibody did not alter the basal level of
binding. The binding of nonmetastatic LNCaP cells to
vitronectin was not altered by SDF-1 (Fig. 2C), while
inclusion of the anti-avb3 receptor antibody reduced
binding to below the baseline level in the presence of
SDF-1 (Fig. 2C).
To investigate whetheravb3 receptors regulate SDF-1-
induced invasion of extracellular matrix by prostate
cancer cells, we used an in vitro assay of invasion. SDF-1
stimulated invasion of an artificial extracellular matrix
(Matrigel) by PC3 and LNCaP C4-2B cells but not
LNCaP cells (Fig. 3). The addition of the anti-avb3
receptor antibody LM609 blocked the SDF-1-induced
augmentation of invasion, whereas an isotype-matched
control antibody had no such effect (Fig. 3A–C).
Collectively, these observations demonstrate that the
SDF-1/CXCR4 axis mediates the activation of avb3
receptor by SDF-1 to modulate adhesion and invasion
of extracellular matrix by prostate cancer cells.
SDF-1Transiently Increasesb3mRNAExpression
inMetastatic Prostate Cancer Cell Lines
We examined the effects of SDF-1 on av and b3
mRNA expression in prostate cancer cell lines using
real-time reverse transcription-polymerase reaction
(RT-PCR). The relative level of expression of av and b3
mRNA was high in PC3 cells, while LNCaP C4-2B cells
expressed high levels ofav mRNA but considerably less
b3 mRNA compared to PC3 cells, and the nonmetastatic
LNCaP cells expressed low levels of both transcripts
(Fig. 4A,B). SDF-1 stimulation for 2 hr (Fig. 4C) or
longer (4, 8, and 24 hr; data not presented) did not alter
the expression of av mRNA in any of the cell lines
examined. SDF-1 significantly increased b3 mRNA
expression in PC3 and LNCaP C4-2B cells but had no
effect on LNCaP cells (Fig. 4D).
SDF-1Enhances the Expression andActivation
of avb3 Receptors in Cancer Prostate Cells
Flow cytometry was used to examine the effects of
SDF-1 on avb3 receptor protein expression in prostate
cancer cell lines. In the absence of SDF-1, the highly
metastatic PC3 cells expressed the highest amount of
avb3 receptor protein, LNCaP C4-2B cells expressed
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Fig. 2. SDF-1a enhances the binding of prostate cancer cells to
bonematrixproteinsviaavb3 receptors.Prostate cancercellswere
pretreatedwithvehicle(control),ananti-avb3receptorantibody,or
an isotype-matched control antibody (IgG) before being seeded
onto vitronectin-coated plates in the presence or absence of SDF-
1a (0 ^200ng/ml) for1hr at 378C.Afterremoving thenonadherent
cells, the adherent cells were counted using the XTT proliferation
assay. The data for the PC3, LNCaP C4-2B, and LNCaP lines of
cancerprostate cells arepresentedin (A), (B), and (C), respectively.
Thevaluesarethepercentageof themean SDnumberofadherent
control cells quantified in three independent investigations, each of
which was performed in triplicate. *P< 0.05, **P< 0.01, and
***P< 0.001versus thecorrespondingvehicle-treatedgroup.
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moderate amounts of avb3 receptor protein, and
LNCaP cells expressed the lowest levels of avb3
receptor protein among the cell lines examined
(Fig. 5A). SDF-1 increased the expression of avb3
receptor protein in PC3 and LNCaP C4-2B cells,
whereas SDF-1 decreased avb3 receptor protein expres-
sion in LNCaP cells (Fig. 5B).
To determine whether SDF-1 altered the affinity of
the avb3 receptor for ligand, prostate cancer cells were
pretreated with SDF-1 for 15–30 min. The ability of
these cells to bind avb3 receptor ligands was probed
using fluorescein isothiocyanate-labeled vitronectin.
SDF-1a significantly increased the binding of vitronec-
tin by PC3 and LNCaP C4-2B cells, but not by LNCaP
cells (Fig. 5C). To distinguish whether the aforemen-
tioned effect was due to an increase in the number of
avb3 receptors expressed or change in receptor affinity,
the effect of SDF-1 on avb3 receptor activation in
prostate cancer cells was evaluated using a monovalent
ligand-mimetic antibody, WOW-1 Fab, which detects
only the activated state of this receptor [32]. SDF-1
treatment for 15 min increased the activation of avb3
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Fig. 3. SDF-1a enhances the invasion of extracellular matrix by
prostate cancer cells via interaction with avb3 receptors. Cancer
prostate cells pretreatedwithvehicle (control), an anti-avb3 recep-
tor antibody, or an isotype-matched control antibody (IgG) were
placedinto theupperchamberof aMatrigelinvasionchamber in the
presence or absence of SDF-1a (200 ng/ml) in the lower chamber;
the chamberswere incubated for 24 hr at 378C.Cells thatmigrated
were countedusing theMTT proliferation assay.The data for PC3,
LNCaP C4-2B, and LNCaP cells are presented in (A), (B), and (C),
respectively as a percentage of the mean SD value of the
untreated controls quantified in three independent investigations,
eachofwhichwasperformedin triplicate. *P< 0.05, **P< 0.01, and
***P< 0.001versus thecorrespondingvehicle-treatedgroup.
Fig. 4. Transcriptional regulation of b3 integrin is modulated by
SDF-1a.Theexpressionb3mRNAinprostatecancercellswasquan-
tified using real-time reverse transcription-polymerase reaction.
Data were normalized to GADPHmRNA expression.A,B: Basal
b3mRNAexpression levels in PC3 cells.C,D: Expression ofav and
b3mRNAincellsstimulatedwithSDF-1a (0,20,or200ng/ml)for2hr.
Datawereobtainedfromthreeindependentexperiments.*P< 0.05
and ***P< 0.001versus the corresponding vehicle-treated control
group.
Fig. 5. SDF-1aenhances theexpressionandactivationofavb3receptors.A:Relativelevelofavb3receptorexpressioninprostatecancercells
detectedusingdirect labelingwith an anti-avb3 receptor antibody (LM609) or an IgGcontrol.B: Expressionofavb3 receptors in cells treated
withvehicle or SDF-1a (200ng/ml) for 30mindeterminedusing fluorescence-activatedcell sorting (FACS) analysis.Thewhite andblackhisto-
gramsrepresentunstimulatedcontrols andSDF-1a-stimulatedcells, respectively.C:Prostate cancercellswere treatedwithvehicle orSDF-1a
(200 ng/ml) for15 ^30 min before the ability of these cells to bind vitronectin labeled with fluorescein isothiocyanate (FITC) was evaluated.
D: Prostate cancer cells were treated with vehicle or SDF-1a (200 ng/ml) for15 ^30 min before expression of activated avb3 receptors was
assayedusingamonovalentligand-mimeticantibody(WOW-1Fab)oraFabcontrol.ThesecondaryantibodywasFITC-labeledgoatanti-mouse
IgG(HþL).Data are fromthreeindependentexperiments.
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receptors by 30% and 23% in PC3 and LNCaP C4-2B
cells, respectively, relative to untreated cells (Fig. 5D).
SDF-1 failed to alter the activation state of avb3
receptors in LNCaP cells (Fig. 5D).
To determine whether SDF-1 enhanced binding of
vitronectin and the WOW-1 antibody by increasing the
number of avb3 receptors expressed or by enhancing
the activation of pre-existing receptors, we examined
the effects of SDF-1 on PC3 cells that were pretreated
with the protein synthesis inhibitor, cyclohexamide
(30 mg/ml, 2 hr). Cyclohexamide decreased the basal
level of vitronectin binding, but SDF-1-stimulated
binding was elevated as early as 15 min after the start
of the addition of cyclohexamide and returned to the
basal level by 30 min (Fig. 6A,D). An increase in the
number of activated avb3 receptors was detected 15 min
after the addition of cyclohexamide, but this increase
began to decline towards the baseline level by 30 min
(Fig. 6B,E). Under the same conditions, total avb3
receptor expression detected using the LM609 antibody
was not altered until 30 min after stimulation with SDF-
1 (Fig. 6C,F). These results indicate that the number of
avb3 receptors expressed on the cell surface increases
over a 30-min period, but that activation of the receptor
in response to SDF-1 is transient and requires the active
recruitment of receptors from intracellular stores.
To determine whether protein trafficking is required
for the stimulatory effects of SDF-1, we tested the effects
of brefeldin A (a metabolite of the fungus Eupenicillium
brefeldianum that specifically and reversibly blocks
protein transport from the endoplasmic reticulum to
the Golgi apparatus [35]) and cytochalasin D (which
inhibits actin polymerization and disrupts receptor
internalization [36]). The binding of vitronectin and the
WOW-1 antibody to avb3 receptors activated by SDF-1
was inhibited by brefeldin A (Fig. 6G,H), whereas
cytochalasin D had no such effect (Fig. 6I and data not
shown). Collectively, these findings suggest that rapid
expression and activation of pre-existing avb3 receptors
likely occurs after SDF-1 binds avb3 receptors and that
this process is independent of actin polymerization and
protein synthesis.
SDF-1Increases Phosphorylation ofb3
Because phosphorylation of b3 is required for avb3
receptor-mediated adhesion to vitronectin [37], we
determined whether SDF-1 altered phosphorylation of
the b3 subunit. As shown in Figure 7A, B, SDF-1 rapidly
increased the phosphorylation of b3 in PC3 and LNCaP
C4-2B cells, but this response was considerably weaker
in LNCaP cells (Fig. 7C).
As SDF-1 binding to CXCR4 activates Gai proteins,
we used a specific inhibitor of Gai proteins, namely
PTX to determine whether the Gai signaling pathway is
required for phosphorylation of b3 [37]. As shown in
Figure 7A, B, pretreatment of SDF-1-stimulated pro-
state cancer cells with PTX significantly inhibited
phosphorylation of b3. To verify these results, we used
C3 transferase, which is an exoenzyme that specifically
ADP-ribosylates Rho proteins and inhibits Rho activa-
tion [38]. The enhanced phosphorylation of b3 induced
by SDF-1 was diminished by pretreatment of cells with
C3 transferase (Fig. 7D,E). These data suggest that Gai
proteins and small GTP-binding proteins (the Rho
family) are involved in SDF-1-induced enhancement of
b3 phosphorylation.
DISCUSSION
We reported previously that the SDF-1/CXCR4 axis
plays a crucial role in directing tumor metastasis to
bone marrow by modulating metastatic cell adhesion
and invasion. However, the molecular mechanisms
that underlie this process are unknown. In the present
study, we focused on the role of the avb3 receptor in the
SDF-1a/CXCR4 axis because this molecule is known to
play a major role in metastasis [25]. We observed that
SDF-1 transiently increased the adhesiveness and
invasiveness of the metastatic prostate cancer cell lines,
PC3, and LNCaP C4-2B (both of which metastsize to
bone), whereas the nonmetastatic prostate cancer cell
line, LNCaP, was unaffected. The affinity of avb3
receptors in the metastatic cell lines increased rapidly
in response to exposure of cells to SDF-1. In addition,
we found that SDF-1-stimulated adhesion and invasion
were inhibited by an anti-avb3 receptor antibody. The
basal level of avb3 receptor mRNA and protein
expression were not markedly different between
LNCaP and LNCaP C4-2B cells, even though these cell
lines exhibit vastly different responses in in vivo meta-
static assays [39]. This prompted us to further explore
the mechanism by which SDF-1 might activate avb3
receptors. Our results suggest that when cells that are
capable of metastasis encounter an environment within
which there is abundant expression of SDF-1 (e.g.,
lymph nodes, liver, or bone marrow), SDF-1 dramati-
cally upregulates b3 mRNA expression and activates
theavb3 receptor. This differential regulation of theavb3
receptor, which depends on the location of receptors as
well as other intrinsic factors, may explain in part why
PC3 and LNCaP C4-2B cells preferentially metastasize
to bone.
It is intuitive that tumors that metastasize to bone
likely target components of the bone matrix for
adhesion; these targets might include protein
sequences that contain the arginine-glycine-aspartate
(RGD) motif that are present in numerous bone matrix
proteins, many of which bind the avb3 receptor (e.g.,
collagens, fibronectin, vitronectin, and osteopontin).
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Fig. 6. Expressionandactivationofavb3receptorsdonotrequireproteinsynthesis.PC3cellswerepretreatedwithvehicle(A^C),cyclohex-
imide (D^F), brefeldinA (G,H), orcytochalasinD (I) beforebeing treatedSDF-1a (200ng/ml) for 0,15, or 30min.Bindingwasdetectedusing
labeledvitronectin (A,D,G, I), theWOW-1Fabmonovalent ligand-mimetic antibodyor a Fab antibodycontrol and anFITC-labeledgoat anti-
mouseIgG(HþL) secondaryantibody(B,E,H),or theanti-avb3 receptor antibodyLM609(C,F) followedbyFACSanalysis.
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These observations are based upon reports that
(a) invasive prostate cancer cell lines (PC3 and
DU145) express avb3 receptors and (b) antibodies
raised against avb3 receptors or the RGD motif inhibit
the binding of extracellular matrix in bone by prostate
cancer cells [27]. Not surprisingly, avb3 receptor
expression has been reported to be correlated with
metastatic potential [40,41]. In line with this finding,
overexpression of the b3 subunit in LNCaP cells
induces a more aggressive metastatic phenotype [27].
Moreover, avb3 receptors bind metargidin, an
adhesion molecule that is also upregulated in meta-
static prostate cancer cells [42,43]. Collectively, these
findings suggest that avb3 receptors play a central role
in the establishment of metastatic prostate cancer
within bone [44].
SDF-1 increases the expression and activation ofavb3
receptors, but the mechanisms that underlie this effect
are unknown. Phosphorylation of the b3 subunit at
Y747 is essential for the activation of small GTP-binding
proteins (the Rho family) [45], and Gai and Rho
proteins are involved in CXCR4 signaling pathways
[46–48]. Activation of Rho is necessary for invasion and
migration in a wide variety of cell types [49]. We found
in the present study that specific inhibition of Gai
proteins with PTX or inhibition of Rho proteins with C3
transferase reduced the SDF-1-induced phosphoryla-
tion of b3. These findings suggest that CXCR4 activates
multiple signaling pathways to alter avb3 receptor
expression and activation.
Enhancement of integrin affinity, avidity, and
integrin–cytoskeleton interactions are all necessary to
permit firm adhesion [45]. Recent studies suggested
that activation of integrin avb3 receptors is crucial for
the arrest and attachment of tumor cells under dynamic
flow conditions [53,54]. The fact that phosphorylation
of b3 is required for avb3 receptor-mediated adhesion to
vitronectin suggests that phosphorylation of b3 permits
The Prostate DOI 10.1002/pros
Fig. 7. SDF-1atreatmentleads tophosphorylationofb3.A^C:Prostate cancercellswerepretreatedwithvehicle (control)orPTX(500ng/
ml) for 1.5 hr before being stimulated with SDF-1a. Proteins in the lysates from the stimulated cells were separated using sodium dodecyl
sulphate^polyacrylamide gel electrophoresis on 8% gels under reducing conditions.The separated proteins were immunoblotted using an
anti-phospho-integrin b3 [pTyr773] antibody.The same blots were later reprobedwith an anti-b3 monoclonal antibody, anti-av antibody, or
anti-a-tubulin antibody.D,E: PC3 (D) and LNCaP C4-2B (D) cells were pretreatedwith the C3 transferase or vehicle (control) to evaluate
Rho function following SDF-1astimulation.Phosphorylatedb3was observed as a bandat130 kDa, nonphosphorylatedb3was observed as a
bandat115kDa,andavwasobservedas abandat150kDa.
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the assembly of a signaling complex at the adhesion site
that may be independent of actin stress fiber generation
[45,50]. Nevertheless, it is unlikely that phosphoryla-
tion of b3 alone is sufficient to activate the receptor;
activation likely requires that a minimum threshold of
phosphorylation be reached and that this is accom-
plished within an appropriate timeframe. For example,
SDF-1 increased the phosphorylation of b3 in LNCaP
cells in the present study (albeit weakly, perhaps due to
a low level of CXCR4 expression [21]). However,
binding of these cells to marrow endothelium is not
altered by SDF-1. One explanation of why SDF-1 does
not affect the binding of these cells may be that
activation of b3 may not reach a minimum threshold.
However, an alternative explanation is that activation
may not have occurred within a requisite time period.
In addition, it is possible that activation of avb3
receptors alone may not be sufficient to enable binding
to occur, which would suggest that binding may
require the participation of other cell adhesion recep-
tors. Indeed, we observed previously that SDF-1
enhances expression of CD164, a receptor thought to
regulate stem-cell metastasis [51,52]. Receptor turnover
and trafficking may also contribute to SDF-1-induced
enhancement of binding, because it is likely very
important that cells mobilize intracellular stores of
preformed avb3 receptors and relocate these receptors
to the cell surface to establish firm adhesive interac-
tions under conditions of flow. Further studies are
required to distinguish between the aforementioned
possibilities.
In summary, SDF-1 enhances the expression and
activation of avb3 receptors in metastatic prostate
cancer cell lines in vitro but does not affect nonmeta-
static prostate cancer cells. The aforementioned effect
of SDF-1 involves an increase in avb3 receptor mRNA
and protein expression and conformational changes to
avb3 receptors that enhance receptor affinity. SDF-1
also increases the phosphorylation of b3, which may be
a key downstream event that results in the activation of
avb3 receptors.
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